Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review

Samiha Mohsen; Philip T. Sobash; Ghada Fahad Algwaiz; Noor Nasef; Safaa Abed Al-Zeidaneen; Nagla Abdel Karim

doi:10.3390/curroncol29030141

Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review

Samiha Mohsen, Philip T. Sobash, Ghada Fahad Algwaiz, Noor Nasef, Safaa Abed Al-Zeidaneen, Nagla Abdel Karim

Pulmonary Disease

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt’s lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.

Original language	English (US)
Pages (from-to)	1695-1708
Number of pages	14
Journal	Current Oncology
Volume	29
Issue number	3
DOIs	https://doi.org/10.3390/curroncol29030141
State	Published - Mar 2022

Keywords

Autophagy
Cancer
Chloroquine
Clinical trial
Hydroxychloroquine
Pevonedistat

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/curroncol29030141

Cite this

@article{e4696c29acf447798cfbba5ecdd8d707,

title = "Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review",

abstract = "Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt{\textquoteright}s lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.",

keywords = "Autophagy, Cancer, Chloroquine, Clinical trial, Hydroxychloroquine, Pevonedistat",

author = "Samiha Mohsen and Sobash, {Philip T.} and Algwaiz, {Ghada Fahad} and Noor Nasef and Al-Zeidaneen, {Safaa Abed} and Karim, {Nagla Abdel}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

doi = "10.3390/curroncol29030141",

language = "English (US)",

volume = "29",

pages = "1695--1708",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "3",

}

TY - JOUR

T1 - Autophagy Agents in Clinical Trials for Cancer Therapy

T2 - A Brief Review

AU - Mohsen, Samiha

AU - Sobash, Philip T.

AU - Algwaiz, Ghada Fahad

AU - Nasef, Noor

AU - Al-Zeidaneen, Safaa Abed

AU - Karim, Nagla Abdel

PY - 2022/3

Y1 - 2022/3

N2 - Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt’s lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.

AB - Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt’s lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.

KW - Autophagy

KW - Cancer

KW - Chloroquine

KW - Clinical trial

KW - Hydroxychloroquine

KW - Pevonedistat

UR - http://www.scopus.com/inward/record.url?scp=85126657577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126657577&partnerID=8YFLogxK

U2 - 10.3390/curroncol29030141

DO - 10.3390/curroncol29030141

M3 - Review article

C2 - 35323341

AN - SCOPUS:85126657577

SN - 1198-0052

VL - 29

SP - 1695

EP - 1708

JO - Current Oncology

JF - Current Oncology

IS - 3

ER -

Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this